Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California. more
Time Frame | CDTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.49% | -2.12% | -3% |
1-Month Return | 53.57% | -3.42% | -0.73% |
3-Month Return | 106.03% | -11.13% | 2.87% |
6-Month Return | 98.46% | -5.74% | 7.17% |
1-Year Return | 54.8% | 3.97% | 25.31% |
3-Year Return | -21.55% | 1.05% | 28.38% |
5-Year Return | -51.83% | 34.37% | 81.89% |
10-Year Return | -92.74% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 20.91M | 12.07M | 49.57M | 64.29M | 63.91M | [{"date":"2019-12-31","value":32.53,"profit":true},{"date":"2020-12-31","value":18.77,"profit":true},{"date":"2021-12-31","value":77.11,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.4,"profit":true}] |
Cost of Revenue | 46.40M | 68.02M | 189.00K | 143.00K | 1.52M | [{"date":"2019-12-31","value":68.22,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.28,"profit":true},{"date":"2022-12-31","value":0.21,"profit":true},{"date":"2023-12-31","value":2.24,"profit":true}] |
Gross Profit | (25.49M) | (55.95M) | 49.57M | 64.29M | 62.38M | [{"date":"2019-12-31","value":-39.64,"profit":false},{"date":"2020-12-31","value":-87.03,"profit":false},{"date":"2021-12-31","value":77.11,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.04,"profit":true}] |
Gross Margin | (121.86%) | (463.66%) | 100.00% | 100.00% | 97.62% | [{"date":"2019-12-31","value":-121.86,"profit":false},{"date":"2020-12-31","value":-463.66,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.62,"profit":true}] |
Operating Expenses | 62.64M | 83.92M | 91.83M | 94.01M | 86.86M | [{"date":"2019-12-31","value":66.63,"profit":true},{"date":"2020-12-31","value":89.27,"profit":true},{"date":"2021-12-31","value":97.68,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.4,"profit":true}] |
Operating Income | (41.72M) | (71.85M) | (42.26M) | (29.72M) | (24.48M) | [{"date":"2019-12-31","value":-4172400000,"profit":false},{"date":"2020-12-31","value":-7184900000,"profit":false},{"date":"2021-12-31","value":-4225500000,"profit":false},{"date":"2022-12-31","value":-2971800000,"profit":false},{"date":"2023-12-31","value":-2448300000,"profit":false}] |
Total Non-Operating Income/Expense | 853.00K | (524.00K) | (424.00K) | 382.00K | 3.99M | [{"date":"2019-12-31","value":21.38,"profit":true},{"date":"2020-12-31","value":-13.13,"profit":false},{"date":"2021-12-31","value":-10.63,"profit":false},{"date":"2022-12-31","value":9.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (41.09M) | (72.11M) | (42.47M) | (29.53M) | (22.49M) | [{"date":"2019-12-31","value":-4109200000,"profit":false},{"date":"2020-12-31","value":-7211100000,"profit":false},{"date":"2021-12-31","value":-4246700000,"profit":false},{"date":"2022-12-31","value":-2952700000,"profit":false},{"date":"2023-12-31","value":-2248800000,"profit":false}] |
Income Taxes | (1.01M) | 262.00K | 1.44M | 272.00K | 443.00K | [{"date":"2019-12-31","value":-69.83,"profit":false},{"date":"2020-12-31","value":18.17,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":18.86,"profit":true},{"date":"2023-12-31","value":30.72,"profit":true}] |
Income After Taxes | (40.09M) | (72.37M) | (43.91M) | (29.80M) | (22.93M) | [{"date":"2019-12-31","value":-4008500000,"profit":false},{"date":"2020-12-31","value":-7237300000,"profit":false},{"date":"2021-12-31","value":-4390900000,"profit":false},{"date":"2022-12-31","value":-2979900000,"profit":false},{"date":"2023-12-31","value":-2293100000,"profit":false}] |
Income From Continuous Operations | (41.09M) | (72.11M) | (42.47M) | (29.80M) | (22.93M) | [{"date":"2019-12-31","value":-4109200000,"profit":false},{"date":"2020-12-31","value":-7211100000,"profit":false},{"date":"2021-12-31","value":-4246700000,"profit":false},{"date":"2022-12-31","value":-2979900000,"profit":false},{"date":"2023-12-31","value":-2293100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (40.09M) | (72.37M) | (43.91M) | (29.80M) | (22.93M) | [{"date":"2019-12-31","value":-4008500000,"profit":false},{"date":"2020-12-31","value":-7237300000,"profit":false},{"date":"2021-12-31","value":-4390900000,"profit":false},{"date":"2022-12-31","value":-2979900000,"profit":false},{"date":"2023-12-31","value":-2293100000,"profit":false}] |
EPS (Diluted) | (1.43) | (1.81) | (0.84) | (0.48) | (0.24) | [{"date":"2019-12-31","value":-143,"profit":false},{"date":"2020-12-31","value":-181,"profit":false},{"date":"2021-12-31","value":-84,"profit":false},{"date":"2022-12-31","value":-48,"profit":false},{"date":"2023-12-31","value":-24,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CDTX | |
---|---|
Cash Ratio | 2.87 |
Current Ratio | 3.54 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CDTX | |
---|---|
ROA (LTM) | -15.66% |
ROE (LTM) | -153.39% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CDTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.29 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.71 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CDTX | |
---|---|
Trailing PE | NM |
Forward PE | 5.75 |
P/S (TTM) | 4.72 |
P/B | 2.20 |
Price/FCF | NM |
EV/R | 2.92 |
EV/Ebitda | NM |
PEG | NM |
Cidara Therapeutics Inc (CDTX) share price today is $23.22
Yes, Indians can buy shares of Cidara Therapeutics Inc (CDTX) on Vested. To buy Cidara Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CDTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cidara Therapeutics Inc (CDTX) via the Vested app. You can start investing in Cidara Therapeutics Inc (CDTX) with a minimum investment of $1.
You can invest in shares of Cidara Therapeutics Inc (CDTX) via Vested in three simple steps:
The 52-week high price of Cidara Therapeutics Inc (CDTX) is $24.99. The 52-week low price of Cidara Therapeutics Inc (CDTX) is $10.
The price-to-earnings (P/E) ratio of Cidara Therapeutics Inc (CDTX) is
The price-to-book (P/B) ratio of Cidara Therapeutics Inc (CDTX) is 2.20
The dividend yield of Cidara Therapeutics Inc (CDTX) is 0.00%
The market capitalization of Cidara Therapeutics Inc (CDTX) is $246.23M
The stock symbol (or ticker) of Cidara Therapeutics Inc is CDTX